Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system

Keith R. Hildebrand, Dennis E. Elsberry, Valerie Anderson

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

With the exception of morphine, hydromorphone is the most commonly used intrathecal opioid for the treatment of intractable pain. The purpose of this study was to evaluate the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. Hydromorphone solution was incubated at 37°C in infusion system reservoirs and with individual materials which comprise the fluid pathway of the infusion system. Stability was analyzed using high performance liquid chromatography; mechanical integrity of device materials was evaluated after drug exposure. After 4 months of exposure to device materials or intact devices, hydromorphone concentration remained greater than 95% of starting material. All device materials retained acceptable mechanical performance. These results demonstrate that hydromorphone is stable at physiological temperatures for at least 4 months in an implantable infusion system and that current clinical practice of refilling the pump every 3 months is appropriate.

Original languageEnglish (US)
Pages (from-to)1042-1047
Number of pages6
JournalJournal of Pain and Symptom Management
Volume22
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Hydromorphone
Equipment and Supplies
Intractable Pain
Morphine
Opioid Analgesics
High Pressure Liquid Chromatography
Temperature
Pharmaceutical Preparations

Keywords

  • Compatibility
  • Hydromorphone
  • Implantable pump
  • Intrathecal
  • Opioid
  • Stability

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. / Hildebrand, Keith R.; Elsberry, Dennis E.; Anderson, Valerie.

In: Journal of Pain and Symptom Management, Vol. 22, No. 6, 2001, p. 1042-1047.

Research output: Contribution to journalArticle

Hildebrand, Keith R. ; Elsberry, Dennis E. ; Anderson, Valerie. / Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. In: Journal of Pain and Symptom Management. 2001 ; Vol. 22, No. 6. pp. 1042-1047.
@article{640d7ac2274a474cbe26c40b807005c5,
title = "Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system",
abstract = "With the exception of morphine, hydromorphone is the most commonly used intrathecal opioid for the treatment of intractable pain. The purpose of this study was to evaluate the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. Hydromorphone solution was incubated at 37°C in infusion system reservoirs and with individual materials which comprise the fluid pathway of the infusion system. Stability was analyzed using high performance liquid chromatography; mechanical integrity of device materials was evaluated after drug exposure. After 4 months of exposure to device materials or intact devices, hydromorphone concentration remained greater than 95{\%} of starting material. All device materials retained acceptable mechanical performance. These results demonstrate that hydromorphone is stable at physiological temperatures for at least 4 months in an implantable infusion system and that current clinical practice of refilling the pump every 3 months is appropriate.",
keywords = "Compatibility, Hydromorphone, Implantable pump, Intrathecal, Opioid, Stability",
author = "Hildebrand, {Keith R.} and Elsberry, {Dennis E.} and Valerie Anderson",
year = "2001",
doi = "10.1016/S0885-3924(01)00364-5",
language = "English (US)",
volume = "22",
pages = "1042--1047",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system

AU - Hildebrand, Keith R.

AU - Elsberry, Dennis E.

AU - Anderson, Valerie

PY - 2001

Y1 - 2001

N2 - With the exception of morphine, hydromorphone is the most commonly used intrathecal opioid for the treatment of intractable pain. The purpose of this study was to evaluate the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. Hydromorphone solution was incubated at 37°C in infusion system reservoirs and with individual materials which comprise the fluid pathway of the infusion system. Stability was analyzed using high performance liquid chromatography; mechanical integrity of device materials was evaluated after drug exposure. After 4 months of exposure to device materials or intact devices, hydromorphone concentration remained greater than 95% of starting material. All device materials retained acceptable mechanical performance. These results demonstrate that hydromorphone is stable at physiological temperatures for at least 4 months in an implantable infusion system and that current clinical practice of refilling the pump every 3 months is appropriate.

AB - With the exception of morphine, hydromorphone is the most commonly used intrathecal opioid for the treatment of intractable pain. The purpose of this study was to evaluate the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. Hydromorphone solution was incubated at 37°C in infusion system reservoirs and with individual materials which comprise the fluid pathway of the infusion system. Stability was analyzed using high performance liquid chromatography; mechanical integrity of device materials was evaluated after drug exposure. After 4 months of exposure to device materials or intact devices, hydromorphone concentration remained greater than 95% of starting material. All device materials retained acceptable mechanical performance. These results demonstrate that hydromorphone is stable at physiological temperatures for at least 4 months in an implantable infusion system and that current clinical practice of refilling the pump every 3 months is appropriate.

KW - Compatibility

KW - Hydromorphone

KW - Implantable pump

KW - Intrathecal

KW - Opioid

KW - Stability

UR - http://www.scopus.com/inward/record.url?scp=0035217856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035217856&partnerID=8YFLogxK

U2 - 10.1016/S0885-3924(01)00364-5

DO - 10.1016/S0885-3924(01)00364-5

M3 - Article

C2 - 11738167

AN - SCOPUS:0035217856

VL - 22

SP - 1042

EP - 1047

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 6

ER -